XML 62 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Schedule of Third Party Net Sales by Major Customers
The following table represents the percentage of consolidated third party net sales to Mylan’s major customers during the years ended December 31, 2017, 2016, and 2015.
 
Percentage of Third Party Net Sales
 
2017
 
2016
 
2015
McKesson Corporation
13
%
 
16
%
 
15
%
AmerisourceBergen Corporation
8
%
 
14
%
 
16
%
Cardinal Health, Inc.
10
%
 
11
%
 
12
%
Reconciliation of Segment Information to Total Consolidated Information
Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.
(In millions)
North America
 
Europe
 
Rest of World
 
Corporate / Other
 
Consolidated
Year Ended December 31, 2017
 
 
 
 
 
 
 
 
 
Third party net sales
$
4,969.6

 
$
3,958.3

 
$
2,832.1

 
$
—

 
$
11,760.0

Other revenue
86.5

 
36.5

 
24.7

 
—

 
147.7

Intersegment revenue
74.6

 
112.4

 
379.2

 
(566.2
)
 
—

Total
$
5,130.7

 
$
4,107.2

 
$
3,236.0

 
$
(566.2
)
 
$
11,907.7

 
 
 
 
 
 
 
 
 
 
Segment profitability
$
2,497.1

 
$
1,082.8

 
$
650.9

 
$
(2,793.7
)
 
$
1,437.1

Year Ended December 31, 2016
 
 
 
 
 
 
 
 
 
Third party net sales
$
5,629.5

 
$
2,953.8

 
$
2,383.8

 
$
—

 
$
10,967.1

Other revenue
88.4

 
12.6

 
8.8

 
—

 
109.8

Intersegment revenue
45.4

 
106.3

 
407.6

 
(559.3
)
 
—

Total
$
5,763.3

 
$
3,072.7

 
$
2,800.2

 
$
(559.3
)
 
$
11,076.9

 
 
 
 
 
 
 
 
 
 
Segment profitability
$
2,921.2

 
$
669.4

 
$
423.5

 
$
(3,312.5
)
 
$
701.6

Year Ended December 31, 2015
 
 
 
 
 
 
 
 
 
Third party net sales
$
5,100.4

 
$
2,205.6

 
$
2,056.6

 
$
—

 
$
9,362.6

Other revenue
55.3

 
5.3

 
6.1

 
—

 
66.7

Intersegment revenue
26.5

 
109.9

 
378.0

 
(514.4
)
 
—

Total
$
5,182.2

 
$
2,320.8

 
$
2,440.7

 
$
(514.4
)
 
$
9,429.3

 
 
 
 
 
 
 
 
 
 
Segment profitability
$
2,720.8

 
$
421.5

 
$
320.7

 
$
(2,002.1
)
 
$
1,460.9
Net Third Party Sales Classified Based on Therapeutic Product Categories
The Company’s third party net sales are generated via the sale of products in the following therapeutic franchises:
 
Year Ended December 31,
(In millions)
2017
 
2016
 
2015
Central Nervous System and Anesthesia
$
2,238.2

 
$
2,030.4

 
$
1,724.7

Respiratory and Allergy
1,382.5

 
1,813.1

 
1,500.3

Infectious Disease
1,463.2

 
1,303.0

 
1,322.2

Cardiovascular
1,219.5

 
1,165.1

 
1,075.3

Gastroenterology
1,114.5

 
1,029.3

 
830.5

Diabetes and Metabolism
947.1

 
972.0

 
935.2

Oncology
700.6

 
764.2

 
633.3

Women's Healthcare
711.6

 
593.5

 
467.7

Dermatology
911.0

 
369.5

 
226.6

Immunology
145.4

 
133.1

 
118.1

Other (1) 
926.4

 
793.9

 
528.7

 
$
11,760.0

 
$
10,967.1

 
$
9,362.6

____________
(1) 
Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales.
Net Third Party Sales Classified Based on Geographic Location of Subsidiaries
Third party net sales by country are presented on the basis of geographic location of our subsidiaries:
 
Year Ended December 31,
(In millions)
2017
 
2016
 
2015
United States
$
4,683.7

 
$
5,385.6

 
$
4,848.9

India
1,082.6

 
985.8

 
1,033.4

The Netherlands (1)
117.5

 
88.3

 
66.5

Other countries (2)
5,876.2

 
4,507.4

 
3,413.8

 
$
11,760.0

 
$
10,967.1

 
$
9,362.6

____________
(1) 
Mylan N.V. has its corporate seat in the Netherlands.
(2) 
No other country’s net sales represents more than 10% of consolidated net sales for the years ended December 31, 2017, 2016 and 2015, respectively.